Recent Quotes (30 days)

You have no recent quotes
chg | %

ProMetic Life Sciences Inc.  

(Public, TSE:PLI)   Watch this stock  
Find more results for PLI
2.05
+0.01 (0.49%)
Delayed:   2:53PM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.03 - 2.06
52 week 1.47 - 3.24
Open 2.03
Vol / Avg. 224,588.00/656,397.00
Mkt cap 1.38B
P/E     -
Div/yield     -
EPS -0.18
Shares 668.71M
Beta 2.30
Inst. own     -
May 12, 2017
Q1 2017 Prometic Life Sciences Inc Earnings Release (Estimated)
May 11, 2017
ProMetic Life Sciences Inc Annual Shareholders Meeting (Estimated)
May 10, 2017
Prometic Life Sciences Inc Annual Shareholders Meeting - Webcast
Mar 31, 2017
Q4 2016 Prometic Life Sciences Inc Earnings Call - Webcast
Mar 30, 2017
Q4 2016 ProMetic Life Sciences Inc Earnings Release
  

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -598.71% -675.14%
Operating margin -591.51% -682.88%
EBITD margin - -637.46%
Return on average assets -45.16% -46.06%
Return on average equity -81.47% -82.05%
Employees 389 -
CDP Score - -

Address

440 Armand-Frappier Blvd Suite 300
LAVAL, QC H7V 4B4
Canada
+1-450-7810115 (Phone)
+1-450-7814477 (Fax)

Website links

Description

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Officers and directors

Simon Geoffrey Best Independent Chairman of the Board
Age: 59
Pierre Laurin Ph.D. President, Chief Executive Officer, Non-Independent Director
Age: 76
Gregory L. Weaver Chief Financial Officer
Age: 60
Bruce Pritchard Chief Operating Officer
John Moran M.D. Chief Medical Officer, Director
Age: 69
Patrick Sartore Chief Legal Officer and Corporate Secretary
Stefan Clulow Non-Independent Director
Age: 45
Kenneth H. Galbraith Director
Age: 53
Charles N. Kenworthy Non-Independent Director
Age: 58
Bruce J. Wendel Non-Independent Director
Age: 62